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Abstract
AIM
To analyze the importance of para-aortic node status 
in a series of patients who underwent pancreatico-
duodenectomy (PD) in a single Institution.
METHODS
Between January 2000 and December 2012, 151 
patients underwent PD with para-aortic node dissec-
tion for pancreatic adenocarcinoma in our Institution. 
Patients were divided into two groups: patients with 
negative PALNs (PALNs-), and patients with metastatic 
PALNs (PALNs+). Pathologic factors, including stage, 
nodal status, number of positive nodes and lymph node 
ratio, invasion of para-aortic nodes, tumor’s grading, 
and radicality of resection were studied by univariate 
and multivariate analysis. Survival curves were con-
structed with Kaplan-Meier method and compared with 
Log-rank test: significance was considered as P < 0.05. 
RESULTS
A total of 107 patients (74%) had nodal metastases. 
Median number of pathologically assessed lymph nodes 
was 26 (range 14-63). Twenty-five patients (16.5%) 
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Retrospective Cohort Study
had para-aortic lymph node involvement. Thirty-three 
patients (23%) underwent R1 pancreatic resection. One-
hundred forty-one patients recurred and died for tumor 
recurrence, one is alive with recurrence, and 9 are alive 
and free of disease. Overall survival was significantly 
influenced by grading (P  = 0.0001), radicality of 
resection (P  = 0.001), stage (P  = 0.03), lymph node 
status (P  = 0.04), para-aortic nodes metastases (P  = 
0.02). Multivariate analysis showed that grading was 
an independent prognostic factor for overall survival (P  
= 0.0001), while grading (P  = 0.0001) and radicality 
of resection (P  = 0.01) were prognostic parameters 
for disease-free survival. Number of metastatic nodes, 
node ratio, and para-aortic nodes involvement were 
not independent predictors of disease-free and overall 
survival. 
CONCLUSION
In this experience, lymph node status and para-aortic 
node metastases were associated with poor survival 
at univariate analysis, but they were not independent 
prognostic factors.
Key words: Lymphadenectomy; Pancreas; Pancreatic 
cancer; Pancreatectomy; Lymph node metastasis; Para-
aortic nodes; Survival
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Core tip: Para-aortic node involvement by pancreatic 
cancer is traditionally considered as an advanced disease 
with poor prognosis. We retrospectively examined our 
experience of 151 patients with pancreatic cancer 
who underwent resection and para-aortic lymph nodes 
sampling. Disease-free and overall survival were worse 
in patients with para-aortic nodes metastases, but 
multivariate analysis showed that para-aortic node 
involvement is not an independent prognostic factor after 
resection of pancreatic cancer. So, the decision to make 
pancreatic resection should not be based on the para-
aortic node status only.
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INTRODUCTION
Pancreatic cancer remains a very aggressive disease 
with an overall 5-year survival of only 5%[1]. Surgical 
resection followed by adjuvant therapy continues to be 
the treatment of choice for localized, resectable tumors. 
Lymph nodes status is traditionally one of the most 
important prognostic factor for patients who underwent 
resection for pancreatic cancer[2], but the extent of 
lymphadenectomy in pancreatic cancer surgery is still 
debated[3,4]. Moreover, the total number of removed 
nodes and lymph node ratio were recently reported 
as important indicators of prognosis after surgery[5]. 
Para-aortic nodes involvement (PALNs) is generally 
considered as metastatic disease, and resection is not 
recommended[6,7]. However, some Author reported 
survival benefit after surgery even when para-aortic 
nodes were involved by the tumors; so, the real impact 
of PALNs involvement in pancreatic cancer patients is 
still controversial[8]. Aim of this study was to evaluate 
early and late outcome of pancreatic cancer patients 
who underwent pancreatectomy with sampling of para-
aortic nodes, No. 16b1 according to the Japan Pancreas 
Society classification[9]. 
MATERIALS AND METHODS
Data were obtained from a retrospective analysis of 
a prospective data base of patients who underwent 
pancreaticoduodenectomy (PD) or total pancreatectomy 
with PALNs sampling between January 2000 to 
December 2012 in our Department. During the study 
period, 340 patients underwent PD for pancreatic 
neoplasms: after excluding IPMNs, endocrine tumors, 
cystic neoplasms, pancreatic metastasis, duodenal, 
ampullary, and bile duct cancers, 176 patients underwent 
PD for ductal adenocarcinoma of the pancreas. Of these, 
twenty-five patients who underwent resection after 
performing chemotherapy or chemoradiation for locally 
advanced pancreatic cancer in outside setting, were 
excluded from the study. Finally, 151 patients with 
pancreatic carcinoma were enrolled in this analysis. 
They were divided into two groups: patients with 
negative PALNs (PALNs-), and patients with metastatic 
PALNs (PALNs+). The two groups were compared in 
term of demographic features, comorbidities, surgical 
procedures, perioperative findings, tumor pathological 
characteristics, perioperative outcomes, disease-free 
and overall survival. All patients underwent standardized 
preoperative assessment: routine blood tests and tumor 
markers CEA and CA19-9 determination, abdominal 
ultrasound (US), computed assisted tomography (CT) 
scan, and when needed, Magnetic Resonance Imaging 
or positron emission tomography (PET). CT with angio-
graphic reconstruction was the preferred imaging 
for tumor’s staging. All surgical procedures were per-
formed by the same surgical team. Limited involvement 
of superior mesenteric-portal axis (less than 2 cm), in 
absence of extrapancreatic disease and involvement of 
superior mesenteric artery and/or celiac trunk, was not 
considered as contraindication to surgery. No patient 
underwent neoadjuvant therapy. Nomenclature of 
the Japanese Pancreas Society was selected for nodal 
stations in pancreatic surgery[9]. Resection of the pan-
creas included pylorus-preserving PD for tumors of the 
head of the pancreas and total pancreatectomy when 
resection margin of the pancreas was involved by the 
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tumor, or when pancreatic anastomosis was judged at 
high risk of leakage. All patients underwent standard 
lymph node dissection (5, 6, 8a, 12b1, 12b2, 12c, 13a, 
13b, 14a and 14b right lateral side, 17a, 17b) and para-
aortic sampling. Para-aortic nodes were excised by 
harvesting the lymphocellular aortocaval tissue located 
below the left renal vein until the origin of inferior 
mesenteric artery (station 16b1)[9]. Curative resection 
was defined as tumor’s resection with pathologically 
confirmed negative margins. R1 resection was defined 
as the presence of tumor ≤ 1mm from the margin, 
according to Leeds criteria[10]. Tumor was staged 
according to UICC (TNM) classification[11]. Perioperative 
morbidity and mortality were investigated in both 
groups: operative mortality was defined as death 
within 30 d from operation, or during hospitalization. 
Pancreatic fistula was defined as the drainage of fluid 
with an elevated level of amylase, and graded according 
to the International Study Group of Pancreatic Fistula 
recommendations[12]. Age, stage, lymph-node status, 
number of positive lymph nodes (< 3 or > 3), lymph 
node ratio (number of metastatic/total number of lymph 
nodes), para-aortic node status, grading, and radicality 
of resection were recorded as potentially prognostic 
factors. Operative morbidity, mortality, disease-free and 
overall survival were analyzed. All patients underwent 
regular follow-up that included physical examination, 
abdominal CT or US, tumor markers determination 
every 3 mo for the first 2 years, and every 6 mo, there­
after. Adjuvant gemcitabine-based chemotherapy was 
scheduled for all patients whenever applicable. 
Statistical analysis
The χ 2 test or Fisher’s exact test was used for com-
parison among the two groups. Survival curves were 
constructed with the Kaplan-Meier method and compared 
by the univariate Log­rank test: significance was con­
sidered as p < 0.05. Tumor’s stage, grading, lymph 
node status, number of metastatic lymph nodes, lymph 
node ratio, para-aortic node involvement and radicality 
of resection, were considered as prognostic factors. 
Independent prognostic variables were evaluated with 
a Cox regression hazard model. Statistical analysis was 
performed using the SPSS statistical software package 
(version 18.0; SPSS Inc., Chicago, IL, United States). 
RESULTS
During the study period, 340 patients underwent PD 
for pancreatic neoplasms: after excluding IPMNs, 
endocrine tumors, cystic neoplasms, pancreatic meta-
stasis, duodenal, ampullary, and bile duct cancers, 
176 patients underwent PD for ductal adenocarcinoma 
of the pancreas. Of these, twenty-five patients who 
underwent resection after performing chemotherapy or 
chemoradiation for locally advanced pancreatic cancer 
in outside setting, were excluded from the study. Finally, 
151 consecutive patients with pancreatic carcinoma. 
underwent PD with para-aortic node sampling, and 
were enrolled in this analysis: there were 76 males 
and 75 females with a mean age of 65.4 years (range 
31-85). Their clinical and pathological characteristics 
are summarized in Table 1. One hundred and twelve 
patients (74%) had lymph node metastasis: median 
number of pathologically assessed lymph nodes was 
26 (range 14-63). Para-aortic nodes metastases were 
detected in 25 patients (16.5%): all these patients had 
positive lymph nodes (p = 0.003), and they significantly 
underwent a lower rate of non-radical resection (p = 
0.009). Mean number of dissected para-aortic nodes 
was 5 (range 1-15). There was no operative mortality 
in this series, while overall morbidity rate was 41%: 
complications rate was not different between PALNs+ 
and PALNs- patients (41% and 39%, respectively), 
as well as pancreatic fistula rate (16% and 17%, 
respectively). Reoperation rate was not different in the 
two groups (5% and 6%, respectively). Ninety-five 
percent of PALNs- patients and all patients with PALNs+ 
underwent postoperative Gemcitabine-based adjuvant 
therapy. 
Univariate analysis
Results of univariate analysis are reported in Tables 2 
and 3. Poor tumor differentiation (p < 0.0001), lymph 
node status, high tumor’s stage, para-aortic node involve-
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Total 
(n  = 151)
PALNs- 
(n  = 126)
PALNs+ 
(n  =  25)
P  value
Mean/median age 65/67 65/66 65/68
Sex 
   F   75   59 16 0.13
   M   76   67   9
Type of surgery 
   PD 146 122 24 1.00
   TP     5     4   1
Vascular resection   29   21   8 0.09
Tumor (T) 
   1     6     6   0 0.50
   2   17   14   3 1.00
   3 107   90 17 0.80
   4   21   16   5 0.50
Nodes status (N) 
   Neg   39   39   0   0.003
   Pos 112   87 25
Grading (G)
   1   15   11   4 0.20
   2   89   77 12 0.20
   3   47   38   9 0.60
Radicality 
   Yes 113 100 13   0.009
   No   38   26 12
Adjuvant therapy
   Yes 143 120 23 0.74
   No     8     6   0
Table 1  Comparison of clinicopathological characteristics of 
patients with or without para-aortic nodesinvolvement
PALNs: Para-aortic lymph nodes; PD: Pancreaticoduodenectomy; TP: 
Total pancreatectomy; Grading 1, 2, 3: Well, moderate, poor differentiated 
cancer.
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= 0.005 (Figure 1B), respectively. When the patients 
analyzed for grading were stratified according to PALNs 
involvement, PALNs metastasis was related to survival 
only in G1-G2 differentiated cancers, both for overall 
(p = 0.02) (Figure 2A) and disease-free survival (p = 
0.004) (Figure 2B). 
Multivariate analysis
Multivariate analysis showed that tumor differentiation 
ment and margin involvement were associated with 
poor survival, while grading margin involvement and 
PALNS+ significantly influenced disease-free survival. 
In this experience, the number of involved lymph 
nodes (< 3 or > 3) and the lymph node ratio did not 
impact survival outcome. Median overall and disease-
free survival time were significantly longer in patients 
with PALNs- compared to patients with PALNs+: 25 mo 
vs 19 mo, p = 0.02 (Figure 1A) and 12 mo vs 8 mo, p 
Mean survival time (mo) (95%CI) Median survival time (mo) (95%CI) P  value
Grading (G)
   1-2 39.55 (32.36-46.74)   24.00 (19.87-28.13) < 0.001
   3 16.42 (12.86-19.98)   14.00 (12.57-15.43)
Radicality 
   R0 35.88 (29.46-42.31)   22.00 (18.36-25.64)    0.004
   R1 19.99 (12.62-27.38)   13.00 (11.45-14.55)
Stage
   Ⅰ-Ⅱ 34.82 (28.47-41.18)   21.00 (17.79-24.21)  0.03
   Ⅲ-Ⅳ 23.29 (14.70-31.87)   14.00 (11.40-16.59)
Lymph nodes status
   Neg 43.29 (30.37-56.21)     25.00 (17.055-32.95)  0.04
   Pos 27.27 (22.52-32.02)   18.00 (14.65-21.35)
Number of positive lymph nodes
   < 3 26.62 (20.87-32.35)   19.00 (13.09-24.90)  0.74
   > 3 28.39 (20.04-36.74)   17.00 (12.93-21.07)
Lymph node ratio
   ≤ 0.13 31.31 (23.69-38.93)   20.00 (15.57-24.43)  0.28
   0.13-0.2 25.11 (13.23-36.99) 14.00 (9.87-18.13)
   > 0.2 23.29 (16.98-29.61)   18.00 (14.57-21.43)
Para-aortic lymph nodes status
   Neg 42.06 (29.22-54.89)   25.00 (17.17-32.83)  0.02
   Pos 27.27 (22.54-32.02)   18.00 (14.64-21.35)
Table 2  Univariate overall survival analysis of prognostic factors for patients with pancreatic cancer
Grading 1-2: Well-moderately differentiated cancer; Grading 3: Poor differentiated cancer.
Mean DFI time (mo) (95%CI) Median DFI time (mo) (95%CI) P  value
Grading (G)
   1-2   32.438 (24.808-40.068) 13.000 (8.597-17.403) < 0.01
   3 10.438 (8.011-12.865) 8.000 (7.183-8.817)
Radicality 
   R0   29.886 (22.892-36.880) 12.000 (9.280-14.720)    0.001
   R1 12.708 (6.744-18.671) 8.000 (6.256-9.744)
Staging
   Ⅰ-Ⅱ   27.222 (20.732-33.711) 12.000 (9.814-14.186)    0.126
   Ⅲ-Ⅳ 19.772 (9.939-29.604)   8.000 (6.976-9.0224)
Lymph nodes status
   Neg   34.386 (20.868-47.904) 13.000 (9.523-16.477)    0.106
   Pos   21.468 (16.504-26.432) 10.000 (7.686-12.314)
Number of positive lymph nodes
   < 3   30.817 (21.628-40.006) 10.000 (6.746-13.254)    0.150
   > 3   20.326 (14.615-26.036) 11.000 (8.082-13.918)
lymph node ratio
   ≤ 0.13   30.576 (22.593-38.560) 12.000 (9.211-14.789)    0.155
   0.13-0.2 17.500 (5.595-29.405) 8.000 (6.614-9.366)
   > 0.2   17.397 (11.191-23.603) 13.000 (8.840-17.160)
Para-aortic lymph nodes status
   Neg   28.206 (21.656-34.756) 12.000 (9.808-14.192)    0.005
   Pos 11.957 (6.132-17.781) 8.000 (6.853-9.147)
Table 3  Univariate disease-free survival analysis of prognostic factors for patients with pancreatic cancer
DFI: Disease-free survival; Grading 1-2: Well-moderately differentiated cancer; Grading 3: Poor differentiated cancer.
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was the only independent predictor of long-term survival 
(Table 4), while grading and margin involvement 
were independent prognostic factors for disease-free 
survival (Table 4). When lymph node status, lymph 
node ratio, and margin involvement were excluded from 
multivariate analysis, grading was confirmed to be the 
only independent predictor of disease-free and overall 
survival (p < 0.0001).
Follow-up
One hundred and seventeen patients with PALNs- 
experienced tumor’s recurrence. Among them, 14 were 
long-term survivors (> 5-years) (11%): 5 died for 
recurrent tumor and 9 are still alive without disease. 
Two patients with PALNs+ (8%) survived more than 
five years after operation: one died for local and lung 
recurrences 65 mo after PD associated with venous 
resection, and one is alive with lung metastases 70 mo 
after surgery.
DISCUSSION
In our experience of 151 patients with pancreatic 
adenocarcinoma who had undergone PD and para-
aortic lymph node sampling, the involvement of PALNs 
has been shown in 16.5% of patients, in the range 
previously reported by other studies (10.4-29.4, mean 
17.8%)[4]. PALNs metastasis was associated with 
more advanced disease (lymph node metastases and 
non-radical resection) and with poorer disease-free 
and overall survival. However, multivariate analysis 
of prognostic factors showed that only poor grade 
differentiation of the tumor and non-radical resection 
were associated with poor long-term outcome. Para-
aortic node metastasis was not independent predictor 
of disease-free and overall survival, showing that para-
aortic nodes involvement cannot be considered an 
         overall survival            Disease-free survival
HR (95%CI) P  value HR (95%CI) P  value
Grading 2.518 (1.677-3.780) 0.000 2.266 (1.498-3.428) 0.000
Stage 1.137 (0.676-1.915) 0.628 0.960 (0.570-1.615) 0.877
PALNs status 1.376 (0.776-2.441) 0.275 1.519 (0.869-2.656) 0.143
Table 4  Multivariate analysis for overall survival and disease-free survival in 151 patients resected for pancreatic adenocarcinoma
PALNs: Para-aortic node status.
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Figure 2  Comparison of overall survival (A) and disease-free survival 
(B) curves between patients with PALNs+ and PALNs- in the subgroup of 
G1-G2 grade cancer. PALNs: Para-aortic lymph nodes.
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Figure 1  Comparison of overall survival (A) and disease-free survival (B) 
curves between patients with or without para-aortic nodes involvement. 
PALNs: Para-aortic lymph nodes.
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absolute contraindication to pancreatic resection in 
pancreatic cancer patients. This is in contrast with 
the traditional thought that when positive para-aortic 
nodes have been detected, a systemic disease may 
occur, and surgical resection should be abandoned[13-16]. 
On the other hand, extended lymphadenectomy failed 
the target of prolonging long term survival after PD for 
pancreatic head cancer[17-20]. 
There are increasing reports of long-term survival 
after resection of pancreatic cancer with PALNS+[6,7,21,22], 
and, based on other prognostic parameters, more selec-
tive surgical indication has been suggested. Nappo et 
al[23] prospectively evaluated 135 patients undergoing 
PD and PALNs dissection, and found that survival of 
patients with PALNs+ seems to be comparable to 
that of patients with other lymph nodes involvement: 
the presence of PALNs+ should be not considered an 
absolute contraindication to radical surgery. Multivariate 
survival analysis of N16+ pancreatic cancer patients has 
been performed by several Authors in order to identify 
which patients with PALNs+ may benefit from resection. 
Tumor size[21,24], tumor differentiation[24], and absence of 
venous infiltration[21] have been identified as independent 
prognostic factors. Moreover, adjuvant chemotherapy 
has been shown to significantly improve the survival of 
patients with para-aortic lymph node metastasis[25-27]. 
Recently, Sho et al[28] reported a multicentric retro-
spective analysis of 822 patients who underwent 
pancreatic resection with pathological evaluation of 
PALNs for pancreatic ductal adenocarcinoma: metastatic 
PALNs were associated with poorer survival, but PALNs 
metastasis did not have a significant prognostic value 
at multivariate analysis. Some patients with metastatic 
PALNs may survive for longer than expected after 
pancreatectomy. There are two recent meta-analysis 
evaluating the prognostic impact of positive para-
aortic nodes in pancreatic cancer patients. Paiella et 
al[29] collected 2141 patients (17% with PALNs+) from 
13 eligible studies published in the Literature (most 
retrospective studies): PALNs metastasis was associated 
with poor prognosis, but the definitive avoidance of the 
resection when PALNs+ are detected intraoperatively, 
needs further investigations. More recently, Agalianos et 
al[8], reviewed 10 retrospective and 2 prospective non 
randomized studies including 2467 patients. Although, 
involvement of PALNs was associated with decreased 
survival, the existence of long term survivors among the 
subgroup of patients with positive para-aortic nodes, 
requires further evaluation in order to identify factors 
conditioning more favorable outcome. 
Limitations of our study include its retrospective 
design, the relative small number of patients with PALNs 
metastasis, and the change of medical treatment of 
recurrent tumor that eventually occurred in the study 
period. 
Another critical point is the type of para-aortic nodes 
dissection to be performed, since it is not always re-
ported or appears different in several reports. Japan 
Pancreas Society[9] distinguish four subgroups of para-
aortic lymph nodes: stations 16a1, 16a2, 16b1 and 
16b2, from the aortic hiatus to the aortic bifurcation. 
We routinely dissect station 16b1 because it is easy 
to perform after Kocher’s maneuver and it does 
not increase the postoperative morbidity. Although 
some members of the International Study Group on 
Pancreatic Surgery resect 16b1, because they include 
it in the resection plane, no strong recommendation 
could be formulated on dissecting 16b1 routinely[30]. 
In the literature, there are not adequate data on the 
number of lymph nodes removed, and their metastasis 
rate within the subgroups 16a1, 16a2, 16b1 and 16 
b2. However, Kayahara et al[6] reported that all positive 
lymph nodes were located in the 16M region that 
corresponds to 16a2 and 16b1 stations. Nappo et al[23] 
performed 16a2 and 16b1 nodes dissection, and found 
11.1% overall rate of para-aortic nodal metastases. 
Furthermore, Schwarz et al[16] harvested a 5-cm portion 
of the lymphocellular aortocaval tissue located below 
the left renal vein (16b1 station). The mean ± SD 
number of identified para­aortic nodes per patient was 
4.5 ± 1.1 in the node-positive group and 2.9 ± 1.3 in 
the node negative group. So, complete 16b1 dissection 
seems to be adequate for a better tumor staging and 
should be included in a standard lymphadenectomy[4]. 
In conclusion, our study confirms that para-aortic 
node metastatic rate is relevant in pancreatic cancer 
patients. Survival is significantly decreased in patients 
with PALNs+, but PALNs involvement is not independent 
predictor of survival in these patients. Further large, 
prospective, multicentric studies are necessary to defi­
nitively determine the real role of PALNs involvement 
after resection for pancreatic adenocarcinoma. At 
the moment, it appears that the decision to perform 
pancreatic resection should not be taken on the basis of 
para-aortic lymph node status only. 
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perioperative outcomes, disease-free and overall survival.
Innovations and breakthroughs
In this experience, disease-free and overall survival were worse in patients 
with para-aortic nodes metastases, but multivariate analysis showed that para-
aortic node involvement is not an independent prognostic factor after resection 
of pancreatic cancer. In fact, multivariate analysis of prognostic factors showed 
that only poor grade differentiation of the tumor and non-radical resection were 
associated with poor long-term outcome. Para-aortic node metastasis was not 
independent predictor of disease-free and overall survival, showing that para-
aortic nodes involvement cannot be considered an absolute contraindication to 
pancreatic resection in pancreatic cancer patients. This is in contrast with the 
traditional thought that when positive para-aortic nodes have been detected, a 
systemic disease may occur, and surgical resection should be abandoned. So, 
the decision to make pancreatic resection should not be based on the para-
aortic node status only.
Applications
This study confirms that para-aortic node metastatic rate is relevant in 
pancreatic cancer patients. Survival is significantly decreased in patients with 
PALNs+, but PALNs involvement is not independent predictor of survival in 
these patients. Further large, prospective, multicentric studies are necessary 
to definitively determine the real role of PALNs involvement after resection 
for pancreatic adenocarcinoma. At the moment, it appear that the decision to 
perform pancreatic resection should not be taken on the basis of para-aortic 
lymph node status only. 
Terminology
In this study we have evaluated the presence of PALNs in patients operated 
on for pancreatic head adenocarcinoma. Patients were divided in two groups: 
patients with negative PALNs (PALNs-), and patients with metastatic PALNs 
(PALNs+). 
Peer-review
This is a good study worthy of publication and reports 151 patients undergoing 
pancreaticoduodenectomy for pancreatic adenocarcinoma. The histological 
data on resection margins, lymph node status, etc. is reproducible across other 
data sets. The authors have chosen to concentrate on the presence or absence 
of LN metastases in the para-aortic lymph node groups. In doing so they have 
inevitably ended with very small sub-set analysis from which it is difficult to 
make firm conclusions.
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